David Shaw’s Tonix Pharmaceuticals TNXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$344K Buy
+35,294
New +$417K ﹤0.01% 4429
2022
Q2
– Sell
-8
Closed -$1.15M – 5778
2022
Q1
$1.15M Sell
8
-21
-72% -$3.21M ﹤0.01% 3785
2021
Q4
$6.68M Buy
29
+19
+190% +$6.04M 0.01% 2072
2021
Q3
$4.02M Buy
10
+9
+900% +$4.38M ﹤0.01% 2333
2021
Q2
$834K Buy
+1
New +$735K ﹤0.01% 3690
2016
Q4
– Hold
0
– -$82K – 3598
2016
Q3
– Hold
0
– – – 3298
2016
Q2
– Hold
0
– – – 3046
2016
Q1
– Hold
0
– – – 3004
2015
Q4
– Hold
0
– – – 3012
2015
Q3
– Hold
0
– – – 3370

Other funds holding TNXP

David Shaw's TNXP Position: Q3 2026 in Review

David Shaw opened a new position in Tonix Pharmaceuticals (TNXP) in Q3 2026: 35,294 shares worth $344K. The stake represents ﹤0.01% of the portfolio and ranks #4429 among its holdings. This is a return to the name: David Shaw previously reported a position in TNXP as recently as Q1 2022.

David Shaw first reported a position in TNXP in Q2 2021 and has held it in 5 quarters since. The position peaked at $6.68M in Q4 2021. 113 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

  • David Shaw held 35,294 shares of Tonix Pharmaceuticals worth $344K as of Q3 2026.
  • Tonix Pharmaceuticals was a new David Shaw position in Q3 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q3 2026, its #4429 holding.
  • David Shaw first reported a position in Tonix Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
  • David Shaw's Tonix Pharmaceuticals position peaked at $6.68M in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.